The drug efflux transporters ABCB1 and ABCG2 at the blood-brain barrier limit the delivery
of drugs into the brain. Strategies to overcome ABCB1/ABCG2 have been largely …

Brain metastases encompass nearly 80% of all intracranial tumors. A late stage diagnosis
confers a poor prognosis, with patients typically surviving less than 2 years. Poor survival …

Purpose: Osimertinib is a potent and selective EGFR tyrosine kinase inhibitor (EGFR-TKI) of
both sensitizing and T790M resistance mutations. To treat metastatic brain disease, blood …

The Lazarus effect is a rare condition that happens when someone seemingly dead shows
signs of life. The epidermal growth factor receptor (EGFR) represents a target in the fatal …

Background Neratinib has efficacy in central nervous system (CNS) metastases from HER2-
positive metastatic breast cancer (MBC). We report outcomes among patients with CNS …

The well accepted “free drug hypothesis” for small-molecule drugs assumes that only the
free (unbound) drug concentration at the therapeutic target can elicit a pharmacologic effect …

Epidermal growth factor receptor (EGFR) mutation is one of the key oncogenic mutations in
non-small-cell lung cancer with adenocarcinoma histology. Exon 19 deletions and exon 21 …

Blood–brain barrier is a pivotal factor to be considered in the process of central nervous
system (CNS) drug development, and it is of great significance to rapidly explore the blood …

Numerous molecular mechanisms are being examined in an attempt to discover disease-
modifying drugs to slow down the underlying neurodegeneration in Alzheimer's disease …

Simple Summary Glioblastoma (GBM) is the most common form of primary malignant brain
tumor with a devastatingly poor prognosis. Tumor heterogeneity (cellular, molecular and …